Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/16/2017 06/19/2017 06/20/2017 06/21/2017 06/22/2017 Date
2.4(c) 2.4(c) 2.45(c) 2.38(c) 2.49(c) Last
209 219 162 947 151 719 181 510 310 190 Volume
-0.83% 0.00% +2.08% -2.86% +4.62% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.It designs and develops inhaled therapeutic... 
More about the company
Latest news on PULMATRIX INC
06/15 PULMATRIX, INC. : Change in Directors or Principal Officers, Other Events, Finan..
06/15 PULMATRIX : Amit D. Munshi Joins Pulmatrix's Board of Directors
06/13 ZACKS INITIATES ON PULMATRIX (NASDAQ : Pulm)
06/13 PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
06/13 PULMATRIX : Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned s..
06/09 PULMATRIX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/18 PULMATRIX : Receives Key US Patent for its Inhaled Drug for COPD
05/18 PULMATRIX INC : Today's Research Reports on Biotech Stocks to Watch: Pulmatrix a..
05/17 PULMATRIX INC : Pulmatrix's Unique Inhaled Drug Candidate Has "Blockbuster" Pote..
05/11 PULMATRIX : Appoints Ted Raad, MBA, as Chief Business Officer
More news
Sector news : Bio Therapeutic Drugs
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/16Amit D. Munshi Joins Pulmatrix's Board of Directors  
06/15 ? Pulmatrix Inc (NASDAQ:PULM) Is Once Again Dramatically Undervalued via ?
1
06/13Zacks Initiates on Pulmatrix (NASDAQ:PULM)  
06/13Pulmatrix in-licenses kinase inhibitors from Janssen subsidiary for use with ..
1
06/13Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned .. 
More tweets
Qtime:10
News from SeekingAlpha
06/13 Pulmatrix in-licenses kinase inhibitors from Janssen subsidiary for use with ..
06/13 PREMARKET GAINERS AS OF 9 : 05 am
05/17 Pulmatrix up 21%
05/17 Midday Gainers / Losers
05/17 HEALTHCARE GAINERS / LOSERS AS OF 1 : 00 am
Advertisement
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Full-screen chart
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
Terrance G. McGuire Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC303.39%47
AMGEN18.88%127 827
CELGENE CORPORATION15.49%104 381
GILEAD SCIENCES-1.58%92 098
REGENERON PHARMACEUTIC..42.20%55 965
VERTEX PHARMACEUTICALS83.02%33 756
More Results